^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FBXW7 underexpression

    i
    Other names: FBXW7, F-Box And WD Repeat Domain Containing 7, F-Box And WD Repeat Domain Containing 7, E3 Ubiquitin Protein Ligase, F-Box And WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila), F-Box/WD Repeat-Containing Protein 7, F-Box Protein FBX30, SEL-10, FBX30, SEL10, HCdc4, FBW7, HAgo, F-Box And WD-40 Domain-Containing Protein 7, Archipelago Homolog (Drosophila), Homolog Of C Elegans Sel-10, F-Box Protein SEL-10, Archipelago Homolog, F-Box Protein FBW7, Archipelago, FBXO30, FBXW6, CDC4, FBW6
    Entrez ID:
    55294
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    1year
    Molecular mechanism of FBXW7-mediated ubiquitination modification in nasopharyngeal carcinoma cell proliferation in vitro and in vivo. (PubMed, Pathol Res Pract)
    FBXW7 overexpression promoted HOXA10 ubiquitination-based degradation and further inhibited BMP2 transcription, consequently restricting NPC cell proliferation in vitro and in vivo.
    Preclinical • Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    FBXW7 underexpression • FBXW7 overexpression
    |
    MG132
    1year
    Puerarin Suppresses Glycolysis and Increases Cisplatin Chemosensitivity in Oral Squamous Cell Carcinoma via FBXW7/mTOR Signaling. (PubMed, Nutr Cancer)
    These effects were antagonized by FBXW7 downregulation or treatment with MHY1485. Our results suggest that FBXW7 improves cisplatin chemosensitivity and suppresses glycolysis in oSCC cells, indicating its promising potential as a target for puerarin to regulate the cisplatin sensitivity of oSCC cells.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • PKM (Pyruvate Kinase M1/2)
    |
    FBXW7 underexpression • FBXW7 overexpression
    |
    cisplatin
    1year
    E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination. (PubMed, Lab Invest)
    FBXW7 inhibited tumorigenesis and apoptosis and enhanced radiosensitivity of NSCLC cells in vivo via the SOX9/CDKN1A axis. Overall, FBXW7 inhibited SOX9 expression by promoting SOX9 ubiquitination and proteasome degradation, suppressing the binding of SOX9 to CDKN1A, and upregulating CDKN1A, thereby improving the radiosensitivity of NSCLC cells.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • H2AX (H2A.X Variant Histone)
    |
    FBXW7 underexpression • FBXW7 overexpression • SOX9 expression
    over1year
    MECP2 promotes the migration and invasion of gastric cancer cells by modulating the Notch1/c-Myc/mTOR signaling pathways by suppressing FBXW7 transcription. (PubMed, Am J Cancer Res)
    This study demonstrates that MECP2 promotes the migration and invasion of GC cells by modulating the Notch1/c-Myc/mTOR signaling pathways via suppression of FBXW7 transcription. These findings suggest that MECP2 may be a novel effective therapeutic target in GC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NOTCH1 (Notch 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    FBXW7 underexpression
    almost2years
    E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination. (PubMed, Lab Invest)
    FBXW7 inhibited tumorigenesis and apoptosis and enhanced radiosensitivity of NSCLC cells in vivo via the SOX9/CDKN1A axis. Overall, FBXW7 inhibited SOX9 expression by promoting SOX9 ubiquitination and proteasome degradation, suppressing the binding of SOX9 to CDKN1A, and upregulating CDKN1A, thereby improving the radiosensitivity of NSCLC cells.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • H2AX (H2A.X Variant Histone)
    |
    FBXW7 underexpression • FBXW7 overexpression • SOX9 expression
    2years
    Mcl-1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer. (PubMed, J Cell Mol Med)
    The combination of JQ1 with a Mcl-1 inhibitor (S63845) resensitized the FBW7 knockdown tumours to JQ1 treatment in vivo. Our study paves the way for a novel therapeutic potential of BETis with Mcl-1 inhibitors for BC patients with a low FBW7 expression.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    FBXW7 underexpression
    |
    JQ-1 • S63845